Abstract:Parkinson's disease (PD) is an age-associated neurodegenerative disorder characterized by the death of dopaminergic neurons in the substantia nigra pars compacta. Activation of 5-adenosine monophosphate-activated protein kinase (AMPK) has been suggested to be associated with PD pathogenesis. The aim of the present study was to investigate the effects of the aberrant expression of microRNA-185 (miR-185) in PD. A 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced in vitro model of PD was generated using the human SH-SY5Y dopaminergic neuroblastoma cell line, in order to examine the potential molecular mechanisms underlying the roles of miR-185 in PD. miR-185 expression was assessed in MPTP-treated SH-SY5Y cells using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). In addition, MPTP-treated SH-SY5Y cells were transfected with a miR-185 mimic or scramble miRNA, and flow cytometry was used to evaluate the level of cellular apoptosis. The expression of autophagy markers, including Beclin 1, microtubule-associated protein light chain 3 (LC3) I and LC3II, as well as key molecules involved in the AMPK/mechanistic target of rapamycin (mTOR) signaling pathway, such as phosphorylated (p)-AMPK and p-mTOR, was examined using RT-qPCR and western blot analyses. In addition, SH-SY5Y cells were treated with the AMPK inhibitor, Compound C, and its effects on cellular apoptosis were assessed. The results demonstrated that miR-185 was significantly downregulated in SH-SY5Y cells treated with MPTP at concentrations of >100 mu M when compared with untreated controls. Following transfection with a miR-185 mimic, miR-185 expression in SH-SY5Y cells was significantly increased when compared with blank control cells. Notably, miR-185 overexpression was revealed to significantly reduce the MPTP-induced increase in cellular apoptosis. In addition, the expression levels of Beclin 1, LC3I/II, p-AMPK and p-mTOR were significantly upregulated in MPTP-treated SH-SY5Y cells; whereas miR-185 overexpression significantly downregulated the expression of these factors. Furthermore, miR-185 overexpression significantly suppressed apoptosis of SH-SY5Y cells treated with MPTP plus Compound C when compared with the Compound C group. In conclusion, the results of the present study suggest that overexpression of miR-185 may inhibit autophagy and apoptosis of dopaminergic cells in PD potentially via regulation of the AMPK/mTOR signaling pathway. Therefore, AMPK/mTOR-mediated autophagy and apoptotic signaling pathways may be potential novel therapeutic targets for the development of alternative strategies for the treatment of patients with PD.

Autophagy‐regulating miRNAs: Novel therapeutic targets for Parkinson's disease (Review)

Advances with Micrornas in Parkinson's Disease Research.

Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease

MicroRNAs regulation in Parkinson's disease, and their potential role as diagnostic and therapeutic targets

MicroRNAs Play a Role in Parkinson's Disease by Regulating Microglia Function: From Pathogenetic Involvement to Therapeutic Potential

Dysregulation of autophagy and mitochondrial function in Parkinson's disease.

Autophagy‐associated non‐coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis

An Update on Potential Therapeutic Strategies for Parkinson’s Disease Based on Pathogenic Mechanisms

The autophagy-lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson’s disease

miR-214-3p promotes the pathogenesis of Parkinson's disease by inhibiting autophagy

Parkinson's Disease and MicroRNAs: A Duel Between Inhibition and Stimulation of Apoptosis in Neuronal Cells

MicroRNA Dysregulation in Parkinson’s Disease: A Narrative Review

Mechanistic Evaluation of miRNAs and Their Targeted Genes in the Pathogenesis and Therapeutics of Parkinson's Disease

Mitophagy, a Form of Selective Autophagy, Plays an Essential Role in Mitochondrial Dynamics of Parkinson’s Disease

MicroRNAs Modulating Neuroinflammation in Parkinson's disease

Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease

Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease

Overexpression of Mir‑185 Inhibits Autophagy and Apoptosis of Dopaminergic Neurons by Regulating the AMPK/mTOR Signaling Pathway in Parkinson's Disease

Mitochondrial homeostasis regulation: A promising therapeutic target for Parkinson's disease

Microglial Autophagy in Alzheimer’s Disease and Parkinson’s Disease